Sanguinarine protects against osteoarthritis by suppressing the expression of catabolic proteases
Metrics: PDF 2325 views | HTML 2272 views | ?
Yan Ma1,2, Xuewu Sun1,2, Kangmao Huang1,2, Shuying Shen2, Xianfeng Lin1,2, Ziang Xie1,2, Jiying Wang2, Shunwu Fan1,2, Jianjun Ma1,2 and Xing Zhao1,2
1Department of Orthopaedic Surgery, Sir Run Run Shaw Hospital, Medical College of Zhejiang University, Hangzhou 310016, China
2Key Laboratory of Biotherapy of Zhejiang Province, Hangzhou 310016, China
Xing Zhao, email: [email protected]
Keywords: sanguinarine, chondrocyte, osteoarthritis, catabolic proteases
Received: February 10, 2017 Accepted: March 24, 2017 Published: April 11, 2017
Inflammatory cytokines play critical roles in the pathogenesis of osteoarthritis. Recent studies have demonstrated that natural active substances can serve as alternative therapeutic agents for the prevention and treatment of osteoarthritis. Sanguinarine, an alkaloid isolated from the roots of Sanguinaria canadensis, is known to have anti-inflammatory properties. The aim of the present study was to investigate the therapeutic effect of Sanguinarine against osteoarthritis. Sanguinarine inhibited interleukin-1β-induced expression of matrix metalloproteinase 1, 3, and 13, and A disintegrin and metalloproteinase with thrombospondin motifs-5 in chondrocytes, which involved the nuclear factor-κB and c-Jun N-terminal kinase signalling pathways. Furthermore, the study of interleukin-1β-induced cartilage matrix degradation in an anterior cruciate ligament transection-induced osteoarthritis model revealed that Sanguinarine ameliorated osteoarthritis by inhibiting the expression of matrix metalloproteinase 1, 3, and 13, and A disintegrin and metalloproteinase with thrombospondin motifs-5. In conclusion, we demonstrated for the first time that Sanguinarine suppressed the expression of matrix metalloproteinase 1, 3, and 13, and A disintegrin and metalloproteinase with thrombospondin motifs-5 in vitro, ex vivo, and in vivo, indicating its potential usefulness in treating osteoarthritis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.